Immunic, Inc. (IMUX) Stock

About Immunic, Inc.

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

Immunic, Inc. is led by CEO Daniel Vitt, employs 91 people, headquartered in US, publicly traded since 2014.

Immunic, Inc. (IMUX) stock trades at $7.41 with a market capitalization of $101.11M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.39, reflecting a net loss over the last twelve months, price-to-book of 2.22, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.06 and $17.43, and currently trades 57.5% below its 52-week high.

On profitability, Immunic, Inc. generates a return on equity (ROE) of -157.89% (not meaningful, as shareholders' equity is negative), return on capital employed of -92.16%.

Official website: imux.com

Immunic, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Immunic, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-97.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-112.0M.

Borrowings stand at $1.0M, cash from operations was $-86.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 64.4% over five years, and was 1385.7% in the most recent year.

The share price itself has compounded at -36.5% a year over five years, -5.5% over three, 71.1% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Immunic, Inc. (IMUX) — frequently asked questions